226 related articles for article (PubMed ID: 28071875)
1. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS)
Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
[TBL] [Abstract][Full Text] [Related]
2. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
Health Resources and Services Administration, HHS
Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
[TBL] [Abstract][Full Text] [Related]
3. Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
Health Resources and Services Administration, HHS
Fed Regist; 2017 Sep; 82(188):45511-4. PubMed ID: 28990743
[TBL] [Abstract][Full Text] [Related]
4. Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T; Williams C; Vranek K; Mattingly TJ
Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
[TBL] [Abstract][Full Text] [Related]
5. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
6. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
[TBL] [Abstract][Full Text] [Related]
7. Notice regarding section 602 of the Veterans Health Care Act of 1992 inclusion of outpatient hospital facilities--PHS. Notice.
Fed Regist; 1994 Jun; 59(107):29300-1. PubMed ID: 10135125
[TBL] [Abstract][Full Text] [Related]
8. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
9. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
[TBL] [Abstract][Full Text] [Related]
10. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
11. Exclusion of orphan drugs for certain covered entities under 340B Program. Final rule.
Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS)
Fed Regist; 2013 Jul; 78(141):44016-28. PubMed ID: 23882725
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Zeta LM
Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
[TBL] [Abstract][Full Text] [Related]
13. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
14. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
15. Oncology Transactions and the 340B Drug Pricing Program.
Warren A; Shankar A
J Oncol Pract; 2013 Mar; 9(2):89-91. PubMed ID: 23814516
[TBL] [Abstract][Full Text] [Related]
16. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Clark BL; Hou J; Chou CH; Huang ES; Conti R
Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
[TBL] [Abstract][Full Text] [Related]
17. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
[TBL] [Abstract][Full Text] [Related]
18. Final notice regarding section 602 of the Veterans Health Care Act of 1992 entity guidelines--PHS. Final notice.
Fed Regist; 1994 May; 59(92):25110-4. PubMed ID: 10134125
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
[TBL] [Abstract][Full Text] [Related]
20. Notice regarding section 602 of the Veterans Health Care Act of 1992--rebate option--HRSA. Final notice.
Fed Regist; 1998 Jun; 63(124):35239-42. PubMed ID: 10180635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
